Preliminary fourth quarter neffy® net product revenue of approximately $6.5 millionPreliminary cash, cash equivalents and short-term investments ...

can be repeated at 1 h intervals (max 3 mg/24 h, 6 mg/week) Migranal® nasal spray 4 mg/ml nasal spray ... 80 mg tablets 160–240 mg q.d. divided b.i.d., t.i.d. or q.i.d. Propranolol ER ...

can be repeated at 1 h intervals (max 3 mg/24 h, 6 mg/week) Migranal® nasal spray 4 mg/ml nasal spray ... 80 mg tablets 160–240 mg q.d. divided b.i.d., t.i.d. or q.i.d. Propranolol ER ...

YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth ...

Vistagen , a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study of PH284 in ...

URIs can range from mild to severe, with kittens most profoundly affected. Clinical signs include sneezing, nasal and ocular ...

Topical Gel pre-IND meeting and on track to begin Phase 2a clinical trial in alopecia areata in Q2 2025 Unaudited cash and cash equivalents of approximately $70 million as of December 31, 2024 WARREN, ...

Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October ... In the study, ONP-002 was tested using a nasal spray device.

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.